Alzheimer’s Research UK calls for post-Brexit plan to protect dementia research


Brexit must not delay the development and delivery of the first life-changing treatment for people living with dementia. That was the message Alzheimer’s Research UK had for politicians today during a roundtable hosted by the Exiting the European Union Committee.

Now more than ever, Alzheimer’s Research UK believes that support for global efforts to bring an end to the fear, harm and heartbreak of dementia must be protected.

The meeting, held in Cambridge this afternoon, brought together pharmaceutical companies and research organisations to talk about the future of research in a post-Brexit UK and how to build on the industry’s current progress.

Helen Davies, Alzheimer’s Research UK’s Head of Public Affairs, who spoke at the event, said: “We must have the ability to span borders if we are to continue bridging gaps in dementia research.

“Being a member of the EU has enabled huge amounts of collaboration in not only dementia research, but all forms of medical research. Once the UK has left the EU, it is vital that infrastructure is put in place to continue the important work happening in cross-border research programmes across Europe.

“Brexit must not delay UK patients’ access to new treatments when they become available. To streamline the advancement of new medicines, the government must secure maximum co-operation and alignment with EU regulations.

“One of the greatest concerns following a departure from the EU is how researchers in the UK will maintain or replace investment revenue coming from European sources. Although dementia costs the UK economy £26bn annually, the UK government funds just £90m of research into the condition. As the numbers of people with the condition continue to rise, dementia must be given priority in government strategy if we are to change the progression of the UK’s leading cause of death.

“Now more than ever, Alzheimer’s Research UK believes that support for global efforts to bring an end to the fear, harm and heartbreak of dementia must be protected.”



Alzheimer’s Research UK is the UK’s leading dementia research charity. We fund innovative research with the power to transform lives, campaign for government action, and help people to understand dementia and the progress we’re making with research.

Our people are vital to our mission. Our pioneering spirit is reflected in the energy and drive of our staff – all of whom play a key role in helping realise our vision of a world where people are free from the fear, harm and heartbreak of dementia.

By working at Alzheimer’s Research UK, you will be part of an organisation that has been recognised nationally as an outstanding place to work. In 2020, we were listed 39th in the prestigious Sunday Times 100 Best Not-for-Profit Organisations to Work For. We were also awarded a 2-star accreditation by Best Companies, recognising outstanding levels of workplace engagement and were listed in the 75 Best Companies to Work For in the East of England.

Alzheimer's Research UK